The Prognostic Value of Monocyte Chemoattractant Protein-1/CCL2 in Acute Coronary Syndromes**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 50, Issue 22, 2007, Pages 2125-2127

  Frangogiannis, Nikolaos G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; HEPARIN BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; DIAGNOSTIC VALUE; DISEASE COURSE; EDITORIAL; GENE OVEREXPRESSION; HUMAN; MEASUREMENT; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; T LYMPHOCYTE;

ACUTE CORONARY SYNDROME; ANIMALS; CHEMOKINE CCL2; CORONARY ARTERY DISEASE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 36148957789     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.08.027     Document Type: Editorial

References (14)

1. Nelken N.A., Coughlin S.R., Gordon D., and Wilcox J.N. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 88 (1991) 1121-1127
2. Cushing S.D., Berliner J.A., Valente A.J., et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A 87 (1990) 5134-5138
3. Gu L., Okada Y., Clinton S.K., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2 (1998) 275-281
4. Gosling J., Slaymaker S., Gu L., et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103 (1999) 773-778
5. Schecter A.D., Rollins B.J., Zhang Y.J., et al. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 272 (1997) 28568-28573
6. Lutgens E., Faber B., Schapira K., et al. Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody. Circulation 111 (2005) 3443-3452
7. Frangogiannis N.G. The mechanistic basis of infarct healing. Antioxid Redox Signal 8 (2006) 1907-1939
8. Dewald O., Zymek P., Winkelmann K., et al. CCL2/monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 96 (2005) 881-889
9. Frangogiannis N.G., Ren G., Dewald O., et al. The critical role of endogenous thrombospondin (TSP)-1 in preventing expansion of healing myocardial infarcts. Circulation 111 (2005) 2935-2942
10. Aukrust P., Yndestad A., Smith C., Ueland T., Gullestad L., and Damas J.K. Chemokines in cardiovascular risk prediction. Thromb Haemost 97 (2007) 748-754
11. de Lemos J.A., Morrow D.A., Sabatine M.S., et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107 (2003) 690-695
12. de Lemos J.A., Morrow D.A., Blazing M.A., et al. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 50 (2007) 2117-2124
13. McDermott D.H., Yang Q., Kathiresan S., et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 112 (2005) 1113-1120
14. Bustos C., Hernandez-Presa M.A., Ortego M., et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32 (1998) 2057-2064